PT3607939T - Formulações farmacêuticas compreendendo tenofovir e emtricitabina - Google Patents
Formulações farmacêuticas compreendendo tenofovir e emtricitabinaInfo
- Publication number
- PT3607939T PT3607939T PT191992577T PT19199257T PT3607939T PT 3607939 T PT3607939 T PT 3607939T PT 191992577 T PT191992577 T PT 191992577T PT 19199257 T PT19199257 T PT 19199257T PT 3607939 T PT3607939 T PT 3607939T
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187113P | 2015-06-30 | 2015-06-30 | |
| US201662298373P | 2016-02-22 | 2016-02-22 | |
| US201662301429P | 2016-02-29 | 2016-02-29 | |
| US201662317286P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3607939T true PT3607939T (pt) | 2022-09-12 |
Family
ID=56418608
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT191992577T PT3607939T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas compreendendo tenofovir e emtricitabina |
| PT167396258T PT3316868T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas compreendendo tenofovir e emtricitabina |
| PT221765373T PT4070788T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas |
| PT221765241T PT4070787T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167396258T PT3316868T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas compreendendo tenofovir e emtricitabina |
| PT221765373T PT4070788T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas |
| PT221765241T PT4070787T (pt) | 2015-06-30 | 2016-06-29 | Formulações farmacêuticas |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20170000807A1 (pt) |
| EP (5) | EP3607939B1 (pt) |
| JP (3) | JP6667556B2 (pt) |
| KR (2) | KR102313668B1 (pt) |
| CN (1) | CN107847450A (pt) |
| AU (3) | AU2016287500B2 (pt) |
| BR (1) | BR112017027843A2 (pt) |
| CA (1) | CA2990210C (pt) |
| CL (1) | CL2017003320A1 (pt) |
| CO (1) | CO2017013293A2 (pt) |
| CU (1) | CU20170168A7 (pt) |
| DO (1) | DOP2017000306A (pt) |
| EA (1) | EA201792592A1 (pt) |
| EC (1) | ECSP17084331A (pt) |
| ES (4) | ES2945345T3 (pt) |
| HK (1) | HK1248547A1 (pt) |
| IL (1) | IL256364A (pt) |
| MA (1) | MA50541A (pt) |
| MX (1) | MX2017016806A (pt) |
| PE (1) | PE20180411A1 (pt) |
| PH (1) | PH12017502431A1 (pt) |
| PL (4) | PL4070787T3 (pt) |
| PT (4) | PT3607939T (pt) |
| SI (4) | SI3316868T1 (pt) |
| SV (1) | SV2017005601A (pt) |
| WO (1) | WO2017004244A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357940B (es) | 2012-12-21 | 2018-07-31 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| PL3346995T3 (pl) | 2015-11-09 | 2020-03-31 | Gilead Sciences, Inc. | Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności |
| NZ755597A (en) | 2017-02-17 | 2023-06-30 | Eidos Therapeutics Inc | Processes for preparing ag-10, its intermediates, and salts thereof |
| WO2018153977A1 (en) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| EP3600332B1 (en) * | 2017-03-20 | 2023-12-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hiv post-exposure prophylaxis |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| KR102248165B1 (ko) | 2017-12-07 | 2021-05-06 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| JP2021518381A (ja) | 2018-03-23 | 2021-08-02 | エイドス セラピューティクス，インコーポレイティド | Ａｇ１０を使用するｔｔｒアミロイドーシスの治療方法 |
| US11260047B2 (en) * | 2018-08-17 | 2022-03-01 | Eidos Therapeutics, Inc. | Formulations of AG10 |
| CN111096954B (zh) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | 一种用于抗病毒感染的药物组合物及制备方法 |
| CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
| CN110917197A (zh) * | 2019-12-31 | 2020-03-27 | 常州恒邦药业有限公司 | 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法 |
| TWI728709B (zh) * | 2020-02-19 | 2021-05-21 | 台灣森本生物科技開發股份有限公司 | 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方 |
| CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8294101A (en) | 2000-07-21 | 2002-02-05 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AU2004206827A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| KR101645759B1 (ko) | 2009-02-06 | 2016-08-04 | 길리애드 사이언시즈, 인코포레이티드 | 조합 요법용 정제 |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| EA026138B1 (ru) * | 2012-02-03 | 2017-03-31 | Джилид Сайэнс, Инк. | Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций |
| CA2920811A1 (en) * | 2013-08-14 | 2015-02-19 | Ratiopharm Gmbh | Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| NO2717902T3 (pt) * | 2014-06-20 | 2018-06-23 |
-
2016
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 EP EP23162978.3A patent/EP4233846A3/en active Pending
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en active Application Filing
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active IP Right Grant
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active IP Right Grant
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
-
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
-
2018
- 2018-06-27 HK HK18108248.3A patent/HK1248547A1/zh unknown
-
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
-
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
-
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246978A0 (en) | New paracetamol formulations | |
| PT4070787T (pt) | Formulações farmacêuticas | |
| HK1254343A1 (zh) | 藥物製劑 | |
| ZA201903101B (en) | Pharmaceutical formulations | |
| IL262745A (en) | Improved preparations containing drugs | |
| HK1245653A1 (zh) | 藥物製劑 | |
| IL253177A0 (en) | Pharmacy preparation | |
| ZA201707094B (en) | Pharmaceutical formulations | |
| EP3383371C0 (en) | PHARMACEUTICAL FORMULATION | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| HK1245073A1 (zh) | 藥物組合物 | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| GB201506755D0 (en) | Novel pharmaceutical formulation | |
| GB201511246D0 (en) | Pharmaceutical formulation | |
| IL271908A (en) | Over-compressed pharmaceutical preparations | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| GB201610440D0 (en) | Pharmaceutical formulations | |
| PL3319596T3 (pl) | Farmaceutyczne kompozycje | |
| GB201521456D0 (en) | Pharmaceutical composition | |
| GB201506598D0 (en) | Pharmaceutical compositions | |
| GB201507784D0 (en) | Formulations | |
| GB201505532D0 (en) | Formulations |